New Delhi: Eli Lilly and Company India on Tuesday announced that it has received emergency use approval in the country for its monoclonal antibody drug combination used for treating Covid-19 patients with mild to moderate symptoms.
This will be the second cocktail drug approved by DCGI for emergency use after the drug regulator gave its nod to the antibody cocktail Casirivimab and Imdevimab developed by Roche.
Read:| Dr Reddy's to manufacture baricitinib for Covid treatment
"We are pleased that we have another innovative treatment option to offer India's healthcare providers who continue to be at the forefront of the battle against Covid-19. Lilly is committed to contributing to the alleviation of the Covid-19 pandemic in India and around the world. We will continue to assess and evaluate how our existing portfolio and ongoing research can benefit patients with Covid-19," said Luca Vasini, Managing director, India subcontinent, Lilly India.
Read:| Eli Lilly signs agreements with Cipla, Lupin and Sun Pharma for Covid-19 treatment drug
Bamlanivimab and Etesevimab together can be administered via injection in a restricted manner to adults and paediatrics patients (12 years and older, weighing at least 40 kg) in emergencies at hospitals to treat mild to moderate Covid-19.
According to the company statement, Lilly is engaging in active dialogue with the Indian government and regulatory authorities to donate Bamlanivimab and Etesevimab to speed up access and provide more treatment options for patients with Covid-19.
ANI
Read:| 84-yr-old Haryana man, first in India to get antibody cocktail against Covid mutant
